Indivior Studies Show Monthly Buprenorphine Cuts Relapse Risk, Healthcare Costs
Event summary
- Two studies found monthly injectable buprenorphine (SUBLOCADE®) reduced relapse risk by 3.5x–8.1x compared to other MOUD treatments.
- Patients on SUBLOCADE® had 62% lower bacteremia incidence and significantly fewer healthcare visits than those on daily oral buprenorphine.
- Key relapse risk factors included younger age, male sex, Medicaid coverage, and comorbid substance use disorders.
- Studies analyzed 3,400 patients for relapse risk and 467 vs. 120,000 patients for healthcare utilization outcomes.
The big picture
Indivior’s studies reinforce the growing trend toward long-acting injectables in opioid use disorder (OUD) treatment, which aim to improve adherence and reduce relapse. The findings align with broader healthcare shifts toward value-based care, where treatments that lower acute care utilization are increasingly prioritized. Indivior’s focus on real-world evidence positions it to compete in a market where data-driven outcomes are critical for payer and provider adoption.
What we're watching
- Treatment Adherence
- Whether Indivior can leverage these findings to improve patient retention and reduce relapse rates.
- Healthcare Costs
- The pace at which payers adopt SUBLOCADE® to lower long-term healthcare utilization and costs.
- Regulatory Dynamics
- How these real-world evidence studies may influence regulatory approvals or reimbursement policies.
Related topics